Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
Zacks Investment Research | Jan 07, 2020 08:53PM ET
Amarin Corporation plc (NASDAQ:AMRN) reported preliminary results for 2019 and issued expense guidance for 2020. The stock declined almost 5.4% on Jan 7, possibly due to Amarin’s higher operating expense guidance for 2020.
However, shares of Amarin have rallied 33.6% in the past year against the industry ’s decline of 2.4%.
2019 Preliminary Results
For 2019, the company’s preliminary results indicate total revenues at the upper end of $410-$425 million range or slightly above it. The Zacks Consensus Estimate for the fourth quarter and full year stands at $131.08 million and $419 million, respectively.
The estimated full-year sales indicate growth of nearly 85% from the year-ago period, driven by strong demand for the company’s sole drug, Vascepa. It is approved as an adjunct to diet in order to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. In December, the drug received FDA approval for reducing cardiovascular risk in patients with persistent high cardiovascular risk despite statin therapy. However, the company stated that prescription rates for Vascepa is unlikely to increase immediately.
Meanwhile, the company ended 2019 with approximately $645 million in cash. Amarin also ended the year with no outstanding debt except for remaining balance on its royalty-bearing instrument.
2020 Outlook
Amarin had provided revenue guidance for 2020 following the FDA approval for the cardiovascular indication in December. The company continues to expect revenues for 2020 to be in the range of $650-$710 million, primarily from Vascepa sales. This indicates growth of more than 50% year over year. The company also remains on track to almost double its sales team to 800 in early 2020 to support promotion of Vascepa’s expanded label. It also remains committed to start branded direct-to-consumer promotion of VASCEPA for cardiovascular risk reduction, which is subject to FDA approval.
The Zacks Consensus Estimate of $698.99 million for 2020 lies within the guided range. Although Amarin did not provide any revenue estimates beyond 2020, it expects Vascepa sales to reach billions of dollars.
However, the company expects its operating expenses to increase significantly in 2020 due to increase in its sales team and various promotional programs related to Vascepa. It expects its operating expense to increase approximately $200 to $250 million from expenses incurred in 2019. In the first nine months of 2019, the company’s operating expenses were $250.9 million while in 2018, expenses totaled $282.9 million.
The company also anticipates cash flow to remain negative in the beginning of 2020.
Get The News You Want
Amarin Corporation PLC Price
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.